Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

Br J Dermatol. 2001 Mar;144(3):587-9. doi: 10.1046/j.1365-2133.2001.04089.x.


Background: In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -alpha, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-alpha antibody might be effectively used in the treatment of inflammatory skin diseases.

Objectives: To gather information about the efficacy of an anti-TNF-alpha antibody (infliximab) in the treatment of skin lesions of psoriatic arthritis.

Methods: Six patients with progressive joint disease and psoriatic skin lesions unresponsive to methotrexate therapy were treated with anti-TNF-alpha antibody. The Psoriasis Area and Severity Index was determined before and 10 weeks after initiation of therapy.

Results: Improvement of psoriatic skin lesions was observed in all patients. In addition, a marked improvement of the joint disease was noted.

Conclusions: Therapy with anti-TNF-alpha antibody may be an effective treatment regimen for both psoriatic arthritis and psoriatic skin lesions.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / therapy
  • Dermatologic Agents / therapeutic use*
  • Disease Progression
  • Drug Resistance
  • Humans
  • Infliximab
  • Methotrexate / therapeutic use
  • Psoriasis / pathology
  • Psoriasis / therapy*
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha / immunology


  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Methotrexate